Abstract
Tremendous innovative medical technologies (MedTech) have emerged to improve patients’ clinical benefits in recent years. However, lack of solid data on the long-term clinical effectiveness of innovative MedTech leads to clinical and budget uncertainty. Pay-for-Performance risk sharing arrangements (P4PRSAs) can help to address uncertainty concerns. This study aims to analyze the application and prospect of P4PRSAs for MedTech and provides a reference for the payers and healthcare providers on the value access of innovative MedTech in China.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
